Study Complete
Sponsor ID
20120234
A Phase 1b Study Evaluating AMG 232 alone and in Combination with Trametinib in Acute Myeloid Leukemia
Study Details
Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
Protocol Summary
Primary Outcome Measures
To evaluate the safety and tolerability of AMG 232
Timeframe: 36 months
Characterize the pharmacokinetics of AMG 232 alone and in combination with trametinib when administered orally.
Timeframe: 36 months
Determine the maximum tolerated dose of AMG 232 alone and in combination with trametinib, if possible.
Timeframe: 36 months
Secondary Outcome Measures
Treatment Response
Timeframe: 36 months
Locations
Location
Research Site
Birmingham, AL, United States, 35294
Status
Recruiting
Location
Research Site
Salt Lake City, UT, United States, 84112
Status
Recruiting
Location
Research Site
Buffalo, NY, United States, 14263
Status
Recruiting
Location
Research Site
Seattle, WA, United States, 98101
Status
Recruiting
Location
Research Site
Charlotte, NC, United States, 28204
Status
Recruiting